Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
Planegg/Martinsried, November 8, 2024. Medigene AG ( Medigene or the "Company", FSE: MDG1, Prime Standard ) , an oncology platform company focused on the research and development of T cell receptor ( TCR ) -guided therapies for the treatment of cancer, highlighted recent advances in its ...
| Ticker |
Sentiment |
Impact |
|
MDGEF
|
Neutral
|
8 %
|
|
WXXWY
|
Neutral
|
4 %
|
|
BNTX
|
Neutral
|
4 %
|
